Client News

AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

Mainz Biomed Provides Review of 2025 Highlights

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner

Abivax to be Added to Nasdaq Biotechnology Index

CARBIOS maintains its commitment to build the Longlaville plant and adjusts its timeline

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement